Surround yourself with support as you begin treatment

Learn about a complimentary self-care kit

The self-care kit contains information on the possible of ERBITUX as well as products and suggestions to help with skin care. This kit includes:

A brochure with information about potential skin, nail, and hair changes and helpful tips
Lotions, sunscreen, gentle bathing products, and a nail care kit

Using the tips and materials in the self-care kit may help manage . If you have any questions, please be sure to discuss them with your treatment team. Talk to your doctor to determine if the self-care kit is right for you.

Order now

Learn more about side effects

Caring for your skin, nails, and hair during treatment

(Epidermal Growth Factor Receptor) is a receptor found on both and normal . Because ERBITUX is an EGFR inhibitor, it affects not only tumor cells, but it can also cause changes in the normal cells on your skin, nails, and hair follicles. There are many ways to take care of your skin, nails, and hair before and during ERBITUX treatment. Be sure to talk with your doctor or nurse before starting any self-care treatment.

Lilly Support Services^™: Support and Reimbursement

Lilly Support Services^™ strives to offer reliable and individualized treatment support for eligible patients prescribed a Lilly Oncology product whether they are insured, underinsured, or simply uninsured. Services include help with benefit verification, prior authorization, paying for medicine, and specialty pharmacy coordination.

For more information about the Lilly Support Services^™, call 1-800-LillyRx (1-800-545-5979).

Eligible, commercially insured covered patients may qualify for Savings Card assistance.

Paying for treatment shouldn’t be an additional concern for your loved ones, so we’ve created the Lilly Oncology Infused Products Savings Card Program, which may help you manage treatment costs.

Pay as little as $25 a month^* when eligible and commercially insured with coverage for Erbitux

^*Month is defined as 28 days

Governmental beneficiaries excluded. Eligibility required, terms and conditions apply. Savings subject to monthly and annual limits. Card eligibility and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. PROGRAM IS NOT INSURANCE. Review full terms and conditions at https://erbitux.lilly.com/support#terms-and-conditions .
See below for Full terms and conditions.

Step 1: Eligible, commercially insured covered patients can download and print the savings card application

Download application

Step 2: Complete the patient portion of the application and take it to your physician

Step 3: Your physician will complete their section and return the application to Lilly Support Services^™ for processing

By enrolling in the Lilly Oncology Infused Products Savings Card Program (“Program”) and using the Lilly Oncology Infused Products Savings Card (“Card”), you attest that you meet the eligibility criteria, agree to, and will comply with the terms and conditions described below:

Eligibility:

You have been prescribed one of the following Lilly Oncology medicines (“Covered Medicine”) for an approved use consistent with FDA-approved product labeling: Cyramza^® (ramucirumab) or Erbitux^® (cetuximab);
You are enrolled in a commercial drug insurance plan and have coverage for your prescribed Covered Medicine, but your insurance does not cover the full cost of your prescribed Covered Medicine (i.e., you have a co-pay or coinsurance obligation);
You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE^®/CHAMPUS, or any state prescription drug assistance program;
You are a resident of the United States or Puerto Rico; and
You are 18 years of age or older.

Card Terms and Conditions
You must (a) have commercial drug insurance that covers your prescribed Covered Medicine, but your insurance does not cover the full cost and (b) have a prescription for an approved use consistent with FDA-approved product labeling to pay as little as $25 for each infusion of your prescribed Covered Medicine. The Program will cover your co-pay or coinsurance for your prescribed Covered Medicine less $25, up to a maximum monthly savings of up to wholesale acquisition cost plus usual and customary fees and a separate maximum annual savings of up to $25,000 per calendar year. Card may be used for a maximum of up to 12 infusions per calendar year. After the monthly and/or annual maximum savings are reached, you will be responsible for paying any remaining monthly/annual out-of-pocket costs. Program may provide support for infusions with a date of service that falls within 120 days prior to the date the enrollment form is received by the Program.

To receive Program savings, your healthcare provider must submit a claim for coverage to your medical insurance provider. If your medical insurance provider does not cover the full cost of the claim, your healthcare provider must then submit an Explanation of Benefits (EOB) form and a CMS 1450 or 1500 form to www.LillyOncologyPortal.com within 180 days of the infusion date of your prescribed Covered Medicine. The submitted form must include the name of the insurer and plan and demonstrate that a Covered Medication was the medication administered. You understand and agree that Lilly will make a payment of your Program savings on your behalf to your healthcare provider. Subject to Lilly USA, LLC’s (“Lilly”) right to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

Additional Terms and Conditions
If you have an insurance plan that is participating in an alternate funding program (“AFP”) that requires you to apply to the Lilly Oncology Infused Products Savings Card Program or otherwise pursue specialty drug prescription coverage through an alternate funding vendor as a condition of, requirement for, or prerequisite to coverage of your prescribed Covered Medicine, you are not eligible for and are prohibited from using the Lilly Oncology Infused Products Savings Card Program. AFPs include programs where coverage, reimbursement, or patient out of pocket costs for a product in some way vary based on the availability of a manufacturer co-pay program. AFPs may modify, delay, deny, restrict, or withhold insurance benefits or coverage from patients, or exclude Lilly Products from coverage contingent upon a member’s use of the Lilly Oncology Infused Products Savings Card Program. You agree to inform the Lilly Oncology Infused Products Savings Card Program if you are or become a member of such an alternate funding program. You are responsible for any applicable taxes, fees, and any amount that exceeds the monthly or annual maximum savings. Monthly and annual maximums are set at Lilly’s sole and absolute discretion and may be changed with or without notice at any time for any reason. At its sole discretion and with or without notice, Lilly may reduce, eliminate, or otherwise modify the Card savings for any reason, including but not limited to if your commercial drug insurance plan imposes additional requirements which limits or prevents you from receiving coverage for your prescribed Covered Medicine, only allows partial coverage for your prescribed Covered Medicine, removes coverage for your prescribed Covered Medicine and requires you to utilize the Card, does not provide a material level of financial assistance for the cost of your prescribed Covered Medicine, or does not apply Card payments to satisfy your co-payment, deductible, or coinsurance for your prescribed Covered Medicine.

Program savings are limited to the co-pay or coinsurance costs for your prescribed Covered Medicine only, subject to monthly and annual maximum savings, outlined above. The Program will not cover, and shall not be applied toward, the cost of any dosing procedure, any other healthcare provider service or supply charges or other treatment costs, or any costs associated with a hospital stay. Participation in the Program requires a valid patient HIPAA authorization to enroll in the Program. Card savings are not valid for: Massachusetts residents if an AB-rated generic equivalent is available; California residents if an FDA-approved therapeutic equivalent is available. You must meet the Card eligibility criteria, terms and conditions every time you use the Card. If at any time you begin receiving coverage under any state, federal, or government funded healthcare program, you understand that you will no longer be eligible for the Lilly Oncology Infused Products Savings Card Program and agree to call Lilly Support Services for Oncology Infused Products at 1-800-545-5979 to stop participation. You may not seek reimbursement from your health insurance, any third party, or any health savings, flexible spending, or other healthcare reimbursement accounts, for any amount of the savings received through the Card. By utilizing the Card, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you will notify your Insurance Carrier of your redemption of the Card. Card savings cannot be combined or utilized with any other program, discount, discount card, cash discount card, coupon, incentive, or similar offer involving your prescribed Covered Medicine. You agree that this Card savings is intended solely for the benefit of you, the patient, and that the Card benefits are non-transferable. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade, or to counterfeit the Card. THIS CARD IS NOT INSURANCE. Lilly has the sole right to interpret and apply Card eligibility criteria, and terms and conditions. Card eligibility, and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. Lilly’s sole discretion to terminate, rescind, revoke, or amend Card eligibility criteria and/or Card terms and conditions includes the right to terminate any individual Card if Lilly determines, in its sole discretion, that a patient does not satisfy the Card’s eligibility criteria or is using or has attempted to use the Card inconsistently with these Terms and Conditions. Eligibility criteria, and terms and conditions for the Lilly Oncology Infused Products Savings Card Program may change from time to time; the most current version can be found at https://cyramza.lilly.com/financial-support#terms-and-conditions or https://erbitux.lilly.com/support. You may be required to obtain a new Card, including if any Card terms and conditions have been terminated, rescinded, revoked, or amended by Lilly. Card void where prohibited by law. Subject to Lilly USA, LLC’s right to terminate, rescind, revoke or amend Card eligibility criteria and/or Card terms and conditions which may occur at Lilly’s sole discretion, without notice, and for any reason. Card expires and savings end on 12/31/2026.

TRICARE^® is a registered trademark of the Department of Defense (DoD), DHA.

Other resources

When insurance isn’t enough to pay for treatment or you have no insurance, there are other resources that may help with your financial challenges to get the medication you need.

Lilly Cares^® Foundation

The Lilly Cares Foundation, Inc., a separate nonprofit organization, offers a patient assistance program to help qualifying patients receive Lilly medications at no cost. For more information about Lilly Cares, please visit LillyCares.com.

Independent Patient-Assistance Program Foundations

Lilly Support Services provides information about a number of independent patient-assistance programs that may be able to help underinsured patients get the treatment they need with less financial stress. These foundations are not affiliated with Eli Lilly and Company and are operated independently. Funding availability changes weekly, so contact a Lilly Support Services representative at 1-800-LillyRx (1-800-545-5979) for the most recent updates.

View Foundation List

IMPORTANT SAFETY INFORMATION FOR ERBITUX^® (cetuximab)

Warning:

WARNING: ALLERGIC REACTIONS AND HEART ATTACK

ERBITUX can cause serious and sometimes fatal allergic reactions. Serious allergic reactions due to ERBITUX therapy occurred in 2.2% of patients receiving ERBITUX during clinical studies; 1 patient died. The risk of anaphylactic reactions may be increased in patients with a history of tick bites, red meat allergy, or in the presence of certain antibodies which can react to ERBITUX.

Symptoms can include trouble with breathing (including tightening of the airways, wheezing, or hoarseness), low blood pressure, shock, loss of consciousness, and/or heart attack. Report these signs and symptoms of infusion reactions, as well as fever, and/or chills to your doctor or nurse.
Approximately 90% of the severe allergic reactions occurred with the first treatment with ERBITUX (even if the patient had been premedicated with antihistamines), although some patients experienced their first severe allergic reaction during a later treatment
Your doctor or nurse should watch you closely for these symptoms during treatment and for at least 1 hour following treatment and may need to stop therapy in the event of an allergic reaction. After the allergic reaction resolves, your doctor may be able to restart therapy.
If you have a severe allergic reaction, treatment with ERBITUX must be stopped immediately and not started again

ERBITUX can cause heart attack or sudden death.

Heart attack or sudden death occurred in 2% of 208 patients with head and neck cancer treated with radiation therapy and ERBITUX in a clinical study. Three patients with a prior history of coronary artery disease died within six weeks after receiving the last dose of ERBITUX. One patient with no prior history of coronary artery disease died one day after the last dose of ERBITUX.
Heart problems resulting in death or sudden death occurred in 3% of 219 patients with head and neck cancer treated with ERBITUX and platinum-based chemotherapy with fluorouracil in a clinical study.
Notify your doctor if you have a history of any heart disease

ERBITUX can cause lung disease. Lung disease occurred in less than 0.5% of 1570 patients receiving ERBITUX in clinical trials for colorectal cancer and head and neck cancer; 1 patient died.
- Notify your doctor if you develop shortness of breath, a new or worsening cough and/or chest pain while receiving ERBITUX
- ERBITUX treatment should be stopped if breathing symptoms worsen, and should not be restarted if lung disease is diagnosed
ERBITUX can cause skin problems including an acne-like rash, skin drying and cracking, infections (including infections of the blood, skin, eyes, and lips), swelling of the base of the nails or loss of the nails, inflammation of the eye or eyelid, decreased vision and abnormal hair growth. These symptoms were seen in several clinical trials for colorectal cancer and head and neck cancer with ERBITUX.
- Sun exposure may worsen these effects. Patients taking ERBITUX should wear sunscreen and hats to limit sun exposure during treatment and for 2 months after the last dose of ERBITUX
- Severe reactions with symptoms of rash; blistering of the skin, mouth, eyes, and genitals; and shedding of the skin have been seen in patients treated with ERBITUX. These reactions may be life-threatening and possibly lead to death. It is not clear if these reactions are related to the way ERBITUX works or to an immune response, such as Stevens-Johnson syndrome or toxic epidermal necrolysis. Your doctor may withhold, reduce dose or discontinue ERBITUX based on the severity of these symptoms.
- Notify your doctor if you develop any of these symptoms while receiving ERBITUX
Risks when using ERBITUX with radiation and cisplatin. In a study of 940 patients with head and neck cancer, patients received either a combination of radiation and cisplatin (a cancer drug), or ERBITUX in combination with radiation and cisplatin. Adding ERBITUX resulted in an increase in occurrence of severe or life-threatening redness and sores of the lining of the mouth, lips or throat and other digestive organs; skin reactions caused by certain cancer drugs given after radiation; acne-like rash; heart problems; and blood electrolyte disturbances (compared to radiation and cisplatin alone)
- Side effects resulting in death occurred in 4% of patients in the ERBITUX plus radiation and cisplatin treatment arm, and 3% in the radiation therapy and cisplatin alone treatment arm
- 2% of patients in the ERBITUX plus radiation and cisplatin treatment arm experienced decreased blood flow to the heart, compared to 0.9% in the radiation therapy and cisplatin alone treatment arm
- The main point of the study was to measure how long patients survived before their cancer got worse. Adding ERBITUX to radiation and cisplatin did not improve this measure
ERBITUX when given by itself and in combination with other cancer drugs can cause low levels of magnesium, calcium and potassium.
- Your doctor or nurse should periodically monitor your blood electrolyte levels during and for at least 8 weeks after treatment with ERBITUX, and administer intravenous replacement as needed
If you have colorectal cancer with mutations in the Ras genes, you should not be treated with ERBITUX because you will not benefit from ERBITUX treatment and will experience side effects.
ERBITUX can harm your unborn baby. If you are able to become pregnant, you should use effective contraception during treatment with ERBITUX and for 2 months after the last dose of ERBITUX

What should I tell my healthcare provider doctor before taking ERBITUX?
Before you start treatment with ERBITUX, tell your doctor:

If you have any history of heart disease or a heart condition.
If you have a history of breathing problems or other lung problems.
If you are pregnant or if you plan on becoming pregnant. Because ERBITUX can harm an unborn baby, you should use contraception and not become pregnant during treatment with ERBITUX and for at least 2 months after your last dose of ERBITUX. If you become pregnant during your treatment or within 2 months after your last dose, discuss this with your doctor.
If you are breastfeeding or plan to breastfeed. ERBITUX may be passed through human breast milk. Because of the potential for serious side effects in nursing infants from ERBITUX, you should not breastfeed during ERBITUX therapy and for 2 months after the last dose of ERBITUX.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications.

What are the possible side effects of ERBITUX?

The most common side effects (all grades of severity) reported in patients with head and neck cancer treated with ERBITUX in combination with radiation therapy versus radiation therapy alone (incidence ≥25%) were: feeling weak, fever, nausea, vomiting, weight loss, dehydration, elevated liver enzymes in blood tests, sore throat, acne-like rash, and skin irritation in the radiation area. In areas treated with radiation therapy, the addition of ERBITUX to the radiation therapy increases the risk of damage to surrounding healthy tissues in the area treated with radiation. The most common serious side effects (incidence ≥10%) reported by patients included skin irritation in the radiation area, acne-like rash, and weight loss.
The most common side effects (all grades of severity) in patients with head and neck cancer treated with the European version of ERBITUX in combination with platinum-based chemotherapy with fluorouracil versus chemotherapy alone (incidence ≥25%) were: acne-like rash, nausea, infection, rash, diarrhea and anorexia, a psychological disorder characterized by a loss of appetite. Most common serious side effect (incidence ≥10%) reported by patients in either arm was: infection. ERBITUX results in approximately 22% higher blood levels of cetuximab as compared to the European version of ERBITUX. It is possible that U.S. patients receiving ERBITUX may experience more frequent or severe side effects than patients in the study conducted in Europe.
The most common side effects (all grades of severity) in patients with Epidermal Growth Factor Receptor (EGFR) positive, KRAS wild-type colorectal cancer that has spread to other parts of the body who were treated with the European version of ERBITUX in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) versus FOLFIRI alone (incidence ≥25%) were: abnormal decrease in certain white blood cell counts, diarrhea, sore mouth, fever, anorexia, a psychological disorder characterized by a loss of appetite and rash which includes a rash including acne-like rash. Most common serious side effects (incidence ≥10%) reported by patients in either arm were: abnormal decrease in certain white blood cell counts, acne-like rash, and diarrhea. In this study, the type and severity of side effects seen with European cetuximab were similar to other studies of U.S. patients receiving ERBITUX for metastatic colorectal cancer.
The most common side effects (all grades of severity) in patients with Epidermal Growth Factor Receptor (EGFR) positive, KRAS wild-type colorectal cancer that has spread to other parts of the body who were treated with ERBITUX and supportive care versus supportive care alone (incidence ≥25%) were: rash including shedding of the outer layer of the skin, dry skin, itchy skin, other skin problems, nail changes, feeling tired, fever, other pain, headache, shortness of breath, cough, nausea, constipation, diarrhea, vomiting, sore mouth, infection without decrease in certain white blood cell counts, sensory neuropathy (weakness, numbness and pain from nerve damage usually in the hands and feet) and problems sleeping. Most common serious side effects (incidence ≥10%) reported by patients included: feeling tired, other pain, rash including shedding of the outer layer of the skin, shortness of breath, other intestinal problems and infection without abnormal decrease in certain white blood cell counts.
The most common side effects (all grades of severity) in patients with colorectal cancer that has spread to other parts of the body whose tumors had a protein called Epidermal Growth Factor Receptor (EGFR) treated with ERBITUX and irinotecan were: acne-like rash, feeling weakness or discomfort, diarrhea, and nausea. The most common serious side effects reported included: diarrhea, decrease in white blood cell count, feeling weakness or discomfort, and acne-like rash.
The most common side effects (all grades of severity) in patients with BRAF V600E mutation-positive colorectal cancer that has spread to other parts of the body who were treated with ERBITUX and encorafenib versus ERBITUX with irinotecan or ERBITUX with FOLFIRI (incidence ≥25%) were: fatigue, nausea, diarrhea, acne-like rash, abdominal pain, decreased appetite, joint pain, and rash.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

ERBITUX is available by prescription only.

CE CON ISI_ALL 14SEP2022

INDICATION

Metastatic Colorectal Cancer
ERBITUX^® is approved for the treatment of certain patients who have colorectal cancer that has spread to other parts of the body. Only patients whose tumors are KRAS wild-type (which means they have a KRAS mutation-negative gene), and whose tumors have a protein called epidermal growth factor receptor (EGFR), should receive ERBITUX. An FDA-approved test is used to determine if tumors have these particular traits. Treatment with ERBITUX is given in the following ways:

In combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for patients who are being treated for this type of cancer for the first time
In combination with another chemotherapy drug, irinotecan, for patients whose disease has progressed after receiving chemotherapy with irinotecan
As a single agent:
- For patients whose disease has progressed after receiving both irinotecan and oxaliplatin
- For patients who are unable to tolerate chemotherapy with irinotecan

ERBITUX is not approved to treat colorectal cancer in patients whose tumors have mutations in genes called RAS (often called "RAS mutant"), or in patients for whom the mutational status of the RAS genes is not known.

ERBITUX is approved in combination with encorafenib, for the treatment of adult patients with colorectal cancer that has spread to other parts of the body. Only patients whose tumors are BRAF V600E mutant (which means they have a BRAF V600E mutation-positive gene) and their condition has progressed from a previous treatment should receive ERBITUX with encorafenib. An FDA-approved test is used to determine if tumors have these particular traits.

Head and Neck Cancer
ERBITUX^® is approved:

In combination with radiation therapy for the initial treatment of a certain type of locally or regionally advanced head and neck cancer
In combination with platinum-based chemotherapy and fluorouracil for the initial treatment of patients with a certain type of head and neck cancer whose tumor has returned in the same location or spread to other parts of the body
For use alone to treat patients with a certain type of head and neck cancer whose tumor has returned in the same location or spread to other parts of the body and whose disease has progressed following platinum-based chemotherapy

ERBITUX is available by prescription only.